IDT webinar explores effective RNAi and antisense oligo methods

Integrated DNA Technologies (IDT) will host an informative webinar, entitled ‘Knockdown of lncRNAs: exploring RNAi and antisense oligo methods’, on Tuesday, August 25, 2015. Kim Lennox, a research scientist at IDT and expert in the suppression of gene expression, will present the webinar at 9 am and 1 pm Central Standard Time.

Kim Lennox Research Scientist IDT

The webinar will provide an overview of the issues encountered with long non-coding RNA (lncRNA) research and describe the benefits of antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) for knockdown experiments. Attendees will learn how to apply the strengths of each method for more effective lncRNA knockdown.

The discovery and identification of thousands of non-coding RNA species fundamentally changed the way scientists view the eukaryotic genome. The cellular significance of these has been studied using methods based on ASOs and siRNAs.

ASOs repurpose RNAse H1 in the nucleus, while siRNAs take advantage of the conserved RNAi pathway, with the latter often being the method of choice for knockdown of cytoplasmic RNA species. However, the complex cellular localization of lncRNA, often to the nucleus, has meant that knockdown by siRNAs is not always effective.

This webinar provides insight into the challenges encountered in studying lncRNA by knockdown, as well as the strengths of both ASO and siRNA methods. Attendees will learn how to select the most effective knockdown method based on the specific localization of a target lncRNA, thus, saving time and effort in the lab.

To register for the webinar, please select the desired session on the webinar registration page, or via our website at





Session 1 August 25

9:00 AM

3:00 PM

11:00 PM

Session 2 August 25

1:00 PM

7:00 PM

3:00 AM (August 26)

Follow us on twitter @idtdna for real-time updates and insights.

About IDT

Integrated DNA Technologies, Inc. (IDT) is the largest supplier of custom nucleic acids in the world, serving all areas of life sciences research and development. IDT’s primary business is the production of custom, synthetic nucleic acids for molecular biology applications, including qPCR, sequencing, synthetic biology, and functional genomics. The company manufactures and ships an average of 44,000 custom nucleic acids per day to more than 82,000 customers worldwide. IDT manufacturing locations include facilities in Coralville, Iowa; San Diego, California; Leuven, Belgium; and Singapore.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Integrated DNA Technologies. (2019, June 19). IDT webinar explores effective RNAi and antisense oligo methods. News-Medical. Retrieved on August 21, 2019 from

  • MLA

    Integrated DNA Technologies. "IDT webinar explores effective RNAi and antisense oligo methods". News-Medical. 21 August 2019. <>.

  • Chicago

    Integrated DNA Technologies. "IDT webinar explores effective RNAi and antisense oligo methods". News-Medical. (accessed August 21, 2019).

  • Harvard

    Integrated DNA Technologies. 2019. IDT webinar explores effective RNAi and antisense oligo methods. News-Medical, viewed 21 August 2019,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
You might also like... ×
IDT recognized for best-in-class customer experience